SABCS

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.

Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

Dr. Heather Parsons of Dana-Farber Cancer Institute explains how a liquid biopsy could help patients with breast cancer and their care teams learn vital information.

Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.

Data showed that metabolic and genetic factors could contribute to aggressive tumors in Latin American and non-Hispanic White patients with breast cancer.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer.

Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.

A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.